Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Lilly’s Jaypirca combination significantly delays progression in relapsed CLL

Eli Lilly and Company (NYSE:LLY) announced Monday that its Phase 3 BRUIN CLL-322 trial achieved its primary endpoint, demonstrating that the addition of Jaypirca (pirtobrutinib) to a standard regimen of venetoclax and rituximab significantly extended the time patients lived without their disease worsening.

Leia mais: Lilly’s Jaypirca combination significantly delays progression in relapsed CLL